Agonist
Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues
Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition
Rhythm’s Oral MC4R Agonist Bivamelagon Shows Promising Results in Rare Obesity Type
Rhythm Pharmaceuticals; oral weight-loss drug; bivamelagon; MC4R agonist; Phase 2 trial; hypothalamic obesity; BMI reduction; clinical trial results
Vigil’s Iluzanebart Fails Phase 2 in Rare Neuro Disease; Sanofi Takeover Remains On Track
Vigil Neuroscience; iluzanebart; Phase II IGNITE trial; rare neuro disease; ALSP; Sanofi acquisition; Amgen; TREM2 agonist; VG-3927
BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback
BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases
Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline
Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals
Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations
Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback
AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial
Rosnilimab, PD-1 agonist, rheumatoid arthritis, Phase 2b trial, immune modulation, AnaptysBio, autoimmune disease
FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease
Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist
Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction
Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist
Tris Pharma Achieves Significant Milestone with Non-Opioid Painkiller Cebranopadol in Phase III Trials
Non-opioid pain medication, Cebranopadol, Tris Pharma, Phase III trials, Pain management, Reduced abuse potential, Dual-NMR agonist